The TΑp63/BCL2 axis represents a novel mechanism of clinical aggressiveness in chronic lymphocytic leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006348
Abstract: Key Points High expression of TAp63 is linked to adverse clinical outcomes in CLL. TAp63 contributes to the antiapoptotic phenotype of CLL cells, likely through modulating BCL2 protein expression. read more here.
Keywords: mechanism clinical; axis represents; represents novel; novel mechanism ... See more keywords